Paxalisib for repeat or resistant brain lymphoma
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This Phase 2 study tests paxalisib to shrink or control primary CNS lymphoma that has come back or did not respond to prior treatment. It may help by blocking specific cell-growth signals that can drive this lymphoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 and able to understand and sign consent forms.
- You must have primary CNS lymphoma in the brain/CSF/vitreous that was confirmed by biopsy.
- Your MRI must show measurable or evaluable enhancing (visible) tumor that has recurred or is resistant.
- You need to be well enough to do the study: KPS score 70 or higher, and you must recover from prior treatment side effects to mild levels.
- Your corticosteroid dose must be low (8 mg/day dexamethasone or equivalent) and stable or decreasing for 2 weeks before screening.
- You must be able to have MRI scans and meet blood/organ test limits (kidney, liver, blood counts) within 14 days of starting treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests how well a combination of pembrolizumab, ibrutinib, and rituximab treats primary CNS lymphoma that came back or didn’t respond after prior brain treatment. It may help shrink the lymphoma and control it in the brain and fluid around the brain.
This trial tests a combination of two drugs, epcoritamab and ibrutinib, for people whose lymphoma has come back or not responded to treatment and has spread to the brain or spinal cord. The goal is to see if this combination can help control the disease.
This trial studies camrelizumab (an immune medicine) for primary CNS lymphoma that has come back after standard treatment. It aims to shrink the lymphoma seen on MRI and help control the disease with a new immune-based approach.
This trial tests zanubrutinib (a targeted lymphoma medicine) together with pemetrexed (chemotherapy) for lymphoma that has come back or did not respond well in or around the brain. It may help shrink measurable lymphoma and improve control of disease after prior treatments.
This Phase 2 trial tests a combination medicine (thiotepa plus pomalidomide) for people whose primary central nervous system lymphoma has come back or did not respond to prior chemotherapy. It may help shrink lymphoma in the brain/spinal fluid and improve disease control.
This trial tests a drug called paxalisib in people with a newly diagnosed aggressive brain tumor (glioblastoma) who have just finished standard radiation and chemotherapy. The goal is to see if adding paxalisib can help prevent the tumor from coming back by targeting a specific pathway in the cancer cells.
Hear when a new Primary Central Nervous System Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.